Celcuity's gedatolisib doubled survival benefit vs alpelisib in breast cancer trial
Celcuity announced positive Phase 3 VIKTORIA-1 trial results showing gedatolisib combination regimens reduced disease progression risk by 50% compared to alpelisib in PIK3CA mutant HR+/HER2- breast cancer patients. The results represent a potential major advancement for the company's lead candidate and could support future regulatory approval discussions.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day